Biotech Startups

Exonic develops machine learning models trained on biological data to predict gene therapy designs and genomic regulatory patterns, with initial applications in developing targeted treatments for liver cancer.

2 investors

Exostemtech develops exosome-based therapeutics using platform technologies derived from adult stem cells for treating diseases including osteoarthritis, obesity, diabetes, fatty liver disease, and fibrosis. The company operates in the biotechnology and therapeutic drug development sector.

2 investors

Drug discovery company focused on RNA-targeted small molecule therapeutics for expansion repeat disorders.

2 investors

Expert Intelligence builds AI software for analytical labs in drug development, turning raw instrument data into signed, explainable, LIMS-ready results and surfacing lab-wide trends across instruments, methods, and sites. Its two products, EI Flow and EI Signal, use a proprietary Limited Sample Model to automate in-batch decisions and detect drift, serving regulated pharmaceutical QC, stability, and bioanalysis workflows.</parameter> <parameter name="founders">[]

2 investors

2 investors

2 investors

Eyconis is a clinical-stage biotechnology company developing long-acting ophthalmic therapies for serious eye diseases such as wet age-related macular degeneration and diabetic macular edema using the TransCon technology platform. The company aims to reduce treatment burden for patients by extending the duration between required injections while improving disease control and visual outcomes.

2 investors

Beam Therapeutics develops CRISPR base editing technology to create precision genetic medicines for treating human diseases. The company focuses on therapeutic applications using single-letter DNA modifications.

2 investors

Fable Therapeutics is a biotech company using protein engineering to develop biologics targeting the activin receptor type II (ActR2) pathway for obesity and related metabolic diseases. Its pipeline addresses body composition and broader metabolic health rather than weight loss alone, serving patients with obesity and cardiometabolic comorbidities.

2 investors

Seattle biotech that developed FDY-5301 for cardiac and skeletal muscle injury; ceased operations in February 2026.

2 investors

FASTinov develops phenotypic Antimicrobial Susceptibility Testing (AST) kits that deliver results within 2 hours directly from blood cultures, covering gram negative and gram positive panels. Its CE-marked in vitro diagnostic products serve clinical laboratories in the European Union.

2 investors

Fate Therapeutics develops investigational cellular immunotherapies to treat autoimmune diseases and cancer. The company is conducting clinical trials on product candidates under strict regulatory and ethical standards.

2 investors

Fauna Systems develops biobots (programmable biological systems) that operate autonomously in complex environments. The company's work, based on xenobot research, creates living assemblies derived from cells capable of movement, self-powering, environmental sensing, and collective behavior for applications in science and medicine.

2 investors

FeedVax develops a platform of oral vaccines for fish aimed at aquaculture producers, reducing the need to handle animals and avoiding antibiotic use. The company targets animal production in the agtech and biotech space with a focus on sustainability.

2 investors

FemtoFluidics is an early-stage company positioning around drug discovery, with a tagline referencing applying Moore's Law-style scaling to the field. The site is a pre-launch page and provides limited concrete detail about the product.

2 investors

Developed a next-generation iron chelator for iron overload in transfusion-dependent anemia; acquired by Shire in 2012.

2 investors

2 investors

Find What Matters develops AI tools for R&D process optimization, applying data-efficient, multi-agent AI to accelerate scientific discovery for scientists and engineers in fields such as biotech and materials. Its approach targets the "little data" realities of physical-world experimentation to shorten R&D timelines.

2 investors

Firefly Bio develops antibody-drug conjugates (ADCs) that use novel classes of payloads, drawing on a research team experienced in ADC discovery and development. The company operates in the oncology and immunology biotech space.

2 investors

Firma is a contract research organization that supports clinical trials with decentralized trial capabilities, biometric monitoring, and in-home patient visits. The company serves pharmaceutical and biotech companies conducting drug development across therapeutic areas.

2 investors

First Spark Ventures is a venture capital firm that invests in deep tech startups focused on advanced compute, digital biology and biotech, and cyber-physical systems. It backs companies at pre-seed, seed, and Series A stages and partners with SRI International.

2 investors

FitBiomics develops proprietary probiotic microbes derived from research on the microbiomes of elite athletes and healthy people, offering products such as Nella and V•Nella that are tested for quality, safety, and efficacy. The company operates in the biotech and consumer wellness space, focused on functional health benefits.

2 investors

Creating cancer therapeutics through novel immunology insights; acquired by Bristol-Myers Squibb in April 2015 for $1.3B.

2 investors

2 investors